Galderma Group Balance Sheet Health
Financial Health criteria checks 4/6
Galderma Group has a total shareholder equity of $7.6B and total debt of $2.8B, which brings its debt-to-equity ratio to 37.1%. Its total assets and total liabilities are $12.6B and $4.9B respectively. Galderma Group's EBIT is $626.8M making its interest coverage ratio 1.2. It has cash and short-term investments of $385.0M.
Key information
37.1%
Debt to equity ratio
US$2.83b
Debt
| Interest coverage ratio | 1.2x |
| Cash | US$385.00m |
| Equity | US$7.63b |
| Total liabilities | US$4.95b |
| Total assets | US$12.58b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: PY30's short term assets ($1.8B) exceed its short term liabilities ($1.5B).
Long Term Liabilities: PY30's short term assets ($1.8B) do not cover its long term liabilities ($3.4B).
Debt to Equity History and Analysis
Debt Level: PY30's net debt to equity ratio (32%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if PY30's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable PY30 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: PY30 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 53.9% per year.